Those nine companies include Johnson & Johnson, Pfizer, Merck, Amgen, AbbVie, Bristol-Myers Squibb, Gilead, Celgene, and Eli Lilly.
Mr. Trump took issues with drug companies for shifting production overseas, drug prices and tax inversions.
The SPDR S&P Biotech exchange-traded fund — which tracks pharmaceutical stocks — dropped about 4 percent during Mr. Trump’s press conference, while the iShares Nasdaq Biotechnology Index fell 3 percent, according to the report.
As of Wednesday afternoon, shares of Celgene were down 3.5 percent, Johnson & Johnson was down 1.61 percent, Bristol-Myers was down 5.5 percent, Pfizer was down 2.75 percent, Amgen was down 2.27 percent, Abbvie was down 4.2 percent, Gilead was down 2.3 percent and Eli Lilly was down 2.6 percent. Merck actually rose 1.67 percent, according to the report.
Although the companies’ stocks took a hit following Mr. Trump’s harsh words Wednesday, overall it seems investors aren’t too concerned about his criticisms, as the SPDR S&P Biotech ETF is still up nearly 9 percent since he won the election.
More articles on finance:
NYU Langone billing redesign linked to 10% decline in patient complaints
Massachusetts physicians drive prices with ‘wasteful,’ costly testing, study finds
Massachusetts out-of-network ED physicians charge 798% of Medicare rates: 6 findings
